SELLAS Life Sciences Group Inc buy Maxi_Scalibusa
Start price
23.01.21
/
50%
€4.85
Target price
23.01.22
€50.00
Performance (%)
-9.65%
End price
24.01.22
€4.38
Summary
This prediction ended on 24.01.22 with a price of €4.38. With a performance of -9.65%, the BUY prediction for SELLAS Life Sciences Group Inc by Maxi_Scalibusa closed slightly in the red. Maxi_Scalibusa has 50% into this predictionSELLAS Life Sciences is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, is a cancer immunotherapy being developed for the treatment of acute myeloid leukemia (AML) and ovarian cancer. SELLAS Life Sciences is listed on the NASDAQ stock exchange under the symbol RXII.
AI-generated
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| SELLAS Life Sciences Group Inc | -12.877% | -12.877% | 523.529% | 548.980% |
| iShares Core DAX® | 2,99 % | 3,22 % | 4,27 % | 53,70 % |
| iShares Nasdaq 100 | -1,58 % | -3,17 % | 24,75 % | 76,70 % |
| iShares Nikkei 225® | -2,25 % | -9,92 % | 43,52 % | 60,79 % |
| iShares S&P 500 | -0,01 % | 1,64 % | 20,97 % | 62,81 % |
Comments by Maxi_Scalibusa for this prediction
In the thread SELLAS Life Sciences Group Inc diskutieren
In the thread Trading SELLAS Life Sciences Group Inc
Die von Maxi_Scalibusa gewählte maximale Laufzeit wurde überschritten